Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | NRP1 | O14786 | 2/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | GNPAT | O15228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561158 | 0.85 | GRIN1 (0.44) | EPHX2SMN1; SMN2GRIN1GRIN2A | |
| SCHEMBL6562711 | 0.84 | GRIN1 (0.45) | EPHX2SMN1; SMN2GRIN1GRIN2A | |
| SCHEMBL17104387 | 0.84 | GRIN1 (0.45) | EPHX2SMN1; SMN2GRIN1GRIN2A | |
| SCHEMBL29005731 | 0.80 | C3AR1 (0.43) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL12971304 | 0.80 | C3AR1 (0.43) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL1765043 | 0.78 | C3AR1 (0.45) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL1765039 | 0.78 | C3AR1 (0.45) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL21095440 | 0.78 | C3AR1 (0.42) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL27864032 | 0.78 | C3AR1 (0.42) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 | |
| SCHEMBL5490001 | 0.78 | C3AR1 (0.45) | C3AR1EPHX2SHMT1FOLH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209413-A1 | USE OF ASPARAGUSIC ACID AND DERIVATIVES THEREOF TO TREAT SYMPTOMS AND DISORDERS OF NEUROLOGICAL DISEASE | WREEN JOSEPH (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209413-A1 | USE OF ASPARAGUSIC ACID AND DERIVATIVES THEREOF TO TREAT SYMPTOMS AND DISORDERS OF NEUROLOGICAL DISEASE | WREEN JOSEPH (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209413-A1 | USE OF ASPARAGUSIC ACID AND DERIVATIVES THEREOF TO TREAT SYMPTOMS AND DISORDERS OF NEUROLOGICAL DISEASE | ASNS, ASPH, PMP22 | C3AR1 4056/4885EPHX2 3224/4885SHMT1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.